ArticleFrontiers in cell and developmental biology2021

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin.

Liudmila Lobastova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.